Viking Therapeutics Stock Dips as Merck Licenses Obesity Drug Candidate
Merck’s obesity drug licensing deal with Hansoh Pharma sparked a decline in Viking Therapeutics’ stock, raising questions about a potential Merck acquisition. Despite this, analysts remain optimistic about Viking’s long-term prospects, driven by its promising obesity treatment, VK2735.
Viking Therapeutics Stock Dips as Merck Licenses Obesity Drug Candidate Read More »